clinical trials

A first-of-its-kind stem cell-based treatment for retinitis pigmentosa developed by UC Irvine’s Dr. Henry Klassen, Dr. Jing Yang and colleagues has received consent from the U.S. Food & Drug Administration for use in a clinical trial.

During the first week of October, the Sue & Bill Gross Stem Cell Research Center will sponsor events highlighting UCI’s progress in this promising area.

UCI’s gynecologic oncology group forges what is being called the largest breakthrough for treating ovarian cancer in more than a decade.